AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00562107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symphony DR 2550 and REPLY DR cardiac pacemakers
Description: DDD(R) (SafeR OFF)
Study NCT01630811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuedexta
Description: Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
Study NCT01630811 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given once daily for 7 days.
Study NCT01885234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
Study NCT01885234 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretch exercise
Description: Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
Study NCT04256018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
Study NCT04256018 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LD TSEBT
Description: Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks
Study NCT03750513 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
Description: Given LET optimized IMPT
Study NCT03750513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03750513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00607932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical chart review
Description: 2,4,6 months post baseline
Study NCT00607932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT00607932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study NCT04510571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluating Postoperative Pain After Root Canal Treatment with Protaper Next
Description: Patients were randomly separated into two groups and root canal treatments were completed with Protaper Next file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
Study NCT04510571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluating Postoperative Pain After Root Canal Treatment with Reciproc Blue Files
Description: Patients were randomly separated into two groups and root canal treatments were completed with Reciproc Blue file systems. Instrumentation time for each system was noted and patients were given a pain scale which included visual analog scale for 6, 24, 48 and 72 hours after treatment.Postoperative pain scores and instrumentation times were analyzed statistically with chi square test and student t test.
Study NCT04309747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nanosecond knife liver cancer ablation
Description: This trial is a prospective, multi-center, single-arm clinical trial. Four hospitals with national medical clinical trial institution qualifications are selected as clinical trial centers. Qualified participants will receive nanosecond pulse ablation therapy according to the routine procedures. The results will be recorded according to the requirements of the primary and secondary efficacy indicators. After then, statistical comparisons of effectiveness and safety of the product will be made according to groups.
Study NCT01266083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S
Description: Galinpepimut-S admixed with the adjuvant Montanide following specified schedule
Study NCT01266083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection
Study NCT01266083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide
Description: adjuvant
Study NCT03072849 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary function testing
Description: Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
Study NCT03072849 — intervention group
Intervention type: DRUG
Intervention: FAM Therapy
Description: All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC \<0.8.
Study NCT03495505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiSE-CRT
Description: Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
Study NCT03425799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Study NCT03425799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
Study NCT03762252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.
Study NCT03762252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
Study NCT03378206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hinged 8-figure plate
Description: Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
Study NCT03378206 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional 8-figure plate
Description: Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
Study NCT02202811 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Forced Desynchrony
Description: all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
Study NCT02202811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced Desynchrony
Description: all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
Study NCT00942201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
Study NCT00942201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
Study NCT03192332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent-retriever thrombectomy with revascularization device of the Solitaire™ type
Description: Mechanical thrombectomy with a stent-retriever revascularization device
Study NCT03192332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent-retriever thrombectomy with revascularization device of the Solitaire™ type
Description: Mechanical thrombectomy with a stent-retriever revascularization device
Study NCT03192332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)
Description: Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
Study NCT01599351 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: The radiographic-fluoroscopic system
Description: Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
Study NCT02976467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulacimstat (BAY1142524)
Description: 25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
Study NCT02976467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets are given twice daily over a treatment period of 6 months
Study NCT02857595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Behavioral Weight Loss program
Study NCT02857595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Behavioral Weight Loss program
Study NCT02857595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Nomogram
Study NCT02857595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bite Counter
Study NCT02637141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gluten Challenge
Description: Gluten-free cookies (Finnish rusks)
Study NCT02637141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten Challenge
Description: Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
Study NCT02637141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gluten Challenge
Description: Gluten-containing cookies (Finnish rusks), 1-2 g gluten per serving
Study NCT00857038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline tablets, 100mg daily
Study NCT00857038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 100mg
Study NCT05299788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active external warming
Description: In this study, methods used routinely in the Intensive Care Unit (ICU) such as cotton blankets and socks were used for the control group. In addition to the cotton blankets and socks, electric blankets were used for the patients in the intervention group. In accordance with the literature, the temperature of the electric blanket was set at 38 °C (Celsius) at the beginning and increased to a maximum of 40-41 °C based on the patient's body temperature .
Study NCT05299788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice application
Description: In the intervention group, an ice pack was applied to the incision site for pain control in addition to active external warming. Ice packs at 0-5 °C with external dimensions of 160 × 91 × 34 mm and a filled weight of 363 g that were kept in the fridge were used for ice application. To prevent direct contact of the ice pack with the patient's skin, the ice pack was wrapped in a thin cotton sheath.
Study NCT02573038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
Study NCT01483586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kanglaite gelcap
Description: 3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
Study NCT01483586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite gelcap
Description: 6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
Study NCT04149392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
Study NCT04440371 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus 0.1% ointment twice daily plus NBUVB 3 times weekly
Description: Tacrolimus ointment plus phototherapy NBUVB (Tacrolimus arm)
Study NCT04440371 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol/Betamethasone ointment plus NBUVB
Description: Calcipotriol/Betamethasone ointment once daily plus NBUVB 3 times weekly
Study NCT02761629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-Interferon Alpha-2A
Description: Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
Study NCT02761629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon Alpha-2A
Description: Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
Study NCT02761629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (>/=) 75 kg.
Study NCT02761629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin will be administered as either 1000 milligrams (mg) (2\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing less than (\<) 75 kilograms (kg) or as 1200 mg (3\*200 mg tablets in morning and 3\*200 mg tablets in evening) for participants weighing greater than or equal to (>/=) 75 kg.
Study NCT03048110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788 (ODM-201)
Description: In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.
Study NCT03048110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.
Study NCT03048110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
Study NCT01694992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
Study NCT00654693 — intervention group
Intervention type: OTHER
Intervention: Rapid Response Team
Description: If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
Study NCT00749619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter Lock Solution Taurolidine and Citrate
Study NCT00749619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Catheter Lock Solution :Taurolidine and Citrate and Heparin
Study NCT00749619 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Catheter Lock Solution : Heparin
Study NCT02684318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183 + olaparib
Study NCT01370811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxybutynin and clonidine oral solution treatment A
Study NCT01370811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxybutynin and clonidine oral solution treatment B
Study NCT01370811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxybutynin and clonidine oral solution treatment C
Study NCT01370811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxybutynin and clonidine oral solution treatment D
Description: Placebo
Study NCT04068818 — intervention group
Intervention type: DEVICE
Intervention: ANTERION
Description: Biometry images will be acquired on the ANTERION and the reference device and the image quality and the identification of abnormalities will be assessed by a reading center
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given via minibag/gravity flow.
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Given IV over 30 minutes.
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is >2,000/µL on one occasion after the expected nadir.
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-filgrastim
Description: Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is >2,000/µL on one occasion after the expected nadir.
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
Study NCT01783535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: focal therapy
Description: Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV.
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MESNA
Description: Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
Study NCT01783535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
Study NCT01783535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enucleation
Description: Eye removal due to advanced disease in Strata C and D participants.
Study NCT01783535 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation or proton beam radiation
Description: EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
Study NCT01285713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% Dextrose (D5) in Normal Saline (NS)
Description: D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
Study NCT01285713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline (NS)
Description: NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS